N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning

Sponsor: Muhammad Aamir Latif • ClinicalTrials.gov ID: NCT07777835

Registry updated: 2026-08-20
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Pakistan, being a developing country, is one of the regions with the most cases of organophosphate (OP) poisoning/toxicity. MgSO4 is one of the most promising adjunctive treatments that needs to be tested. This study is being carried out with the objective of comparing the 15-day all-cause mortality rate and the total cumulative atropine requirement during hospitalization between patients receiving adjunctive magnesium sulphate with standard therapy and those receiving standard therapy alone.

Interventions

  • Atropine plus pralidoxime (Drug)
    Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
  • Atropine and pralidoxime with adjunctive MgSO4 (Drug)
    Patients will be treated with standard atropine plus pralidoxime therapy alone.

Eligibility criteria

Inclusion Criteria: * Both genders * Adult patients aged between 18 and 50 years * Confirmed clinical diagnosis of organophosphate poisoning containing insecticide, through the oral route * Adult patients, or their legally authorized representative, who will provide informed consent to participate in the study Exclusion Criteria: * Patients with known allergy to MgSO4 * Patients with documented pre-existing renal impairment (Serum creatinine more than 1.5mg/dl) * Patients with documented pre-existing cardiac impairments (e.g., heart block) * Pregnant or lactating women * Confirmed intake of any other drug or poison * Patients who will be declared dead on arrival or those who expired within 2 hours of presentation

Conditions

Organophosphate Poisoning

Locations

  • Nishtar Hospital/Medical University — Multan, Punjab Province, Pakistan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record